Skip to content
zynerba logo
  • Investors
    • IR Information
    • Stock Information
    • Press Releases
    • Events & Webcasts
    • Presentations
    • Enhanced SEC Filings
    • Analyst Coverage
    • Corporate Governance
    • Investor FAQs
    • IRS Form 8937
    • Investor Contacts
  • News
    • Press Releases
    • Events
  • Publications
    • Manuscripts and Presentations
  • Careers
  • LinkedIn
  • Twitter
  • Our Focus
    • Why Rare?
    • Why Neuropsychiatric Disorders?
    • Why Cannabinoids?
    • Why pharmaceutical manufacturing?
  • Our Pipeline
    • ZygelTM
    • Early Access to Medicine
  • Clinical Trials
  • Our Team
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Patient Resources
    • FXS
    • ASD
    • 22q

Zynerba Press Releases

12 May 21 Zynerba Pharmaceuticals Reports First Quarter 2021 Financial Results and Operating Highlights

5 May 21 Zynerba Pharmaceuticals Announces Phase 3 RECONNECT Trial Design for Zygel™ in Fragile X Syndrome

29 Apr 21 Zynerba Pharmaceuticals Presents Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting

15 Apr 21 Zynerba Pharmaceuticals Announces the Acceptance of Two Posters at the Society of Biological Psychiatry 2021 Virtual Meeting

6 Apr 21 Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

10 Mar 21 Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights

4 Mar 21 Zynerba Pharmaceuticals to Participate in the 33rd Annual ROTH Conference

4 Jan 21 Zynerba Pharmaceuticals to Present at Two January Virtual Investor Conferences

17 Dec 20 Zynerba Pharmaceuticals Provides Regulatory Update on Zygel™ in Fragile X Syndrome

4 Dec 20 Zynerba Pharmaceuticals Presents New Data in Two Posters at the 2020 Annual Meeting of the American Epilepsy Society (AES)

Page 5 of 20 | ‹ Previous1 2 3 4 5 6 7 8 9 Next ›Last »

    This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.

    • Privacy Policy
    • Terms of Use
    • Cookie Notice
    • Accessibility Statement
    • Contact Us

    © 2022 Zynerba Pharmaceuticals, Inc. All rights reserved.

    zynerba inverted logo

    80 W. Lancaster Avenue, Suite 300
    Devon, PA 19333
    484.581.7505